ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Repatha®:Amgen Switzerland AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
C10AX13 - EvolocumabATC-DDD Version 2016. Source: WHO
C - Cardiovascular System
 
C10 - Lipid Modifying Agents
 

The DDDs are based on the treatment of hypercholesterolemia.

C10A - Lipid Modifying Agents, plain

Pantethine, which is also used in the treatment of hyperlipidemi, is classified as a vitamin in A11HA.

C10AX - Other Lipid Modifying Agents

This group comprises all cholesterol and triglyceride reducers, which cannot be classified in the preceding groups.
Icosapent ethyl is classified in C10AX06 - omega-3-triglycerides incl. other esters and acids.
Sulodexide is classified in B01AB.

The DDD for evolocumab is based on dosing every second week.

C10AX13 - Evolocumab
StärkeAdm.RouteNote
 P 
2022 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home